EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Diabetic retinopathy in China: Epidemiology, screening and treatment trends—A review

Xiaorong Li iD, Tien-En Tan iD, Tien Y Wong, Xiaodong Sun iD

Clinical & Experimental Ophthalmology · 2023-08 · 51 (6) · 607-626

DOI: 10.1111/ceo.14269 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 28.06.2023. Verfasst von Xiaorong Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and S…. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Mass Screening. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 124 Literaturangaben. Gefördert von: National Key R&D Program, National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetic retinopathy (DR) is the leading cause of vision impairment in the global working‐age population. In China, with one‐third of the world's diabetes population estimated at 141 million, the blindness prevalence due to DR has increased significantly. The country's geographic variations in socioeconomic status have led to prominent disparities in DR prevalence, screening and management. Reported risk factors for DR in China include the classic ones, such as long diabetes duration, hyperglycaemia, hypertension and rural habitats. There is no national‐level DR screening programme in China, but significant pilot efforts are underway for screening innovations. Novel agents with longer durations, noninvasive delivery or multi‐target are undergoing clinical trials in China. Although optimised medical insurance policies have enhanced accessibility for expensive therapies like anti‐VEGF drugs, further efforts in DR prevention and management in China are required to establish nationwide cost‐effective screening programmes, including telemedicine and AI‐based solutions, and to improve insurance coverage for related out‐of‐pocket expenses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic RetinopathyMass ScreeningHumansChinaPrevalenceRisk Factors

Stichwörter der Autor:innen

ChinaDR managementDR screeningdiabetic retinopathyepidemiology

Autor:innen und Institutionen

  • Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin,…
  • Singapore Eye Research Institute, Singapore, Singapore National Eye Centre, Singapore, Singapore.
  • Duke-National University of Singapore Medical School, Singapore, Singapore.
  • Tsinghua Medicine, Tsinghua University, Beijing, China.
  • Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • National Clinical Research Center for Eye Diseases, Shanghai, China.

ORCID-Profile: Xiaorong Li, Tien-En Tan, Xiaodong Sun

Förderung

  • National Key R&D Program
  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Li, X., Tan, T. E., Wong, T. Y., & Sun, X. (2023). Diabetic retinopathy in China: Epidemiology, screening and treatment trends—A review. Clinical & Experimental Ophthalmology, 51(6), 607-626. https://doi.org/10.1111/ceo.14269

Vancouver

Li X, Tan TE, Wong TY, Sun X. Diabetic retinopathy in China: Epidemiology, screening and treatment trends—A review. Clinical & Experimental Ophthalmology. 2023;51(6):607-626. doi:10.1111/ceo.14269

BibTeX
@article{Li2023,
  author = {Li, Xiaorong and Tan, Tien-En and Wong, Tien Y and Sun, Xiaodong},
  title = {Diabetic retinopathy in China: Epidemiology, screening and treatment trends—A review},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2023},
  volume = {51},
  number = {6},
  pages = {607--626},
  doi = {10.1111/ceo.14269}
}
Kostenlos starten →